All In Biotech

NDA 219008 · Janssen Biotech

Lazcluze

Lazertinib Mesylate · Oral · Kinase Inhibitor

NovelPriority review

CDER novel approval, Aug 19, 2024: To treat non-small cell lung cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Aug 19, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

40

4 Phase 3, 9 recruiting

FAERS reports

865

621 serious, 35 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 5, 2026.

LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 )

Mechanism: Lazertinib is a kinase inhibitor of epidermal growth factor receptor (EGFR) that inhibits EGFR exon 19 deletions and exon 21 L858R substitution mutations at lower concentrations than wild-type EGFR. In human NSCLC cells and mouse xenograft models of EGFR exon 19 deletions or EGFR L858R substitution mutations, lazertinib demonstrated anti-tumor activity. Treatment with lazertinib in combination with amivantamab increased in vivo anti-tumor activity compared to either agent alone in a mouse xenograft model of human NSCLC with an EGFR L858R mutation.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 14, 2025 Supplement 2 · Efficacy Letter
  • Aug 19, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
  • LAZCLUZE · LAZERTINIB MESYLATE EQ 80MG BASE · TABLET, ORAL · Prescription
  • LAZCLUZE · LAZERTINIB MESYLATE EQ 240MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lazertinib" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash162
  • infusion related reaction96
  • paronychia69
  • off label use60
  • neuropathy peripheral53
  • fatigue46
  • diarrhoea41
  • nausea36
  • pruritus35
  • stomatitis32
  • dermatitis acneiform31
  • dyspnoea29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202113
202221
202312
202493
2025330
2026396

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lazcluze (Lazertinib Mesylate)

2024 spending

$7.1M

Beneficiaries

183

398 claims

Per beneficiary

$38,932

$541.74 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$7,124,540

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.